The dipeptidyl peptidase-4 inhibitor teneligliptin improved endothelial dysfunction and insulin resistance in the SHR/NDmcr-cp rat model of metabolic syndrome - Nakagami, H; Pang, Z; Shimosato, T (Hypertens Res, 2014)
et al.